Alectinib in Early-Stage Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Current Evidence and Future Challenges.

Diego Luigi Cortinovis Alessandro Leonetti Alessandro Morabito Luca Sala Marcello Tiseo

Published in: Cancers (2024)

In resectable anaplastic lymphoma kinase-positive lung cancer, adjuvant alectinib represents the new standard of care and could soon be used in perioperative treatment.

Keyphrases

early stage
diffuse large b cell lymphoma
protein kinase
healthcare
palliative care
tyrosine kinase
cardiac surgery
patients undergoing
sentinel lymph node
quality improvement
current status
squamous cell carcinoma
acute kidney injury
combination therapy
lymph node
chronic pain
affordable care act